The state of Indiana used a $2 million grant to lure PDS Biotechnology, a Cincinnati-based company developing nanoparticle treatments for the immune system that could prevent cancer, HPV and several other kinds of infections, according to a press release.
Indiana used money from its 21st Century Research and Technology fund.
PDS had operated in the BioStart incubator in Cincinnati, so it has received some services through the state. But PDS had never receive state funding through Third Frontier or other programs, said Matt Schutte of BioOhio. Three months ago, the U.S. National Cancer Institute’s Nanotechnology Characterization Lab announced it would work with PDS to complete preclinical development of its HPV-cancer therapy.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
